Omeros Corporation - Asset Resilience Ratio
Omeros Corporation (OMER) has an Asset Resilience Ratio of 45.31% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Omeros Corporation working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2007–2025)
This chart shows how Omeros Corporation's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see how large is Omeros Corporation's balance sheet.
Liquid Assets Composition Over Time
This chart breaks down Omeros Corporation's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Omeros Corporation strategic investment ratio to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $129.97 Million | 45.31% |
| Total Liquid Assets | $129.97 Million | 45.31% |
Asset Resilience Insights
- Very High Liquidity: Omeros Corporation maintains exceptional liquid asset reserves at 45.31% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Omeros Corporation Industry Peers by Asset Resilience Ratio
Compare Omeros Corporation's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for Omeros Corporation (2007–2025)
The table below shows the annual Asset Resilience Ratio data for Omeros Corporation.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 49.79% | $162.14 Million | $325.63 Million | +18.49pp |
| 2024-12-31 | 31.30% | $86.73 Million | $277.08 Million | -12.25pp |
| 2023-12-31 | 43.55% | $164.74 Million | $378.27 Million | +12.43pp |
| 2022-12-31 | 31.12% | $183.91 Million | $590.97 Million | +17.65pp |
| 2021-12-31 | 13.47% | $56.46 Million | $419.27 Million | -55.28pp |
| 2020-12-31 | 68.74% | $124.45 Million | $181.04 Million | +26.61pp |
| 2019-12-31 | 42.13% | $57.70 Million | $136.97 Million | -14.82pp |
| 2018-12-31 | 56.95% | $54.64 Million | $95.94 Million | -12.12pp |
| 2017-12-31 | 69.08% | $80.36 Million | $116.33 Million | +5.00pp |
| 2016-12-31 | 64.07% | $43.11 Million | $67.28 Million | +9.17pp |
| 2015-12-31 | 54.90% | $26.90 Million | $48.99 Million | -4.00pp |
| 2014-12-31 | 58.90% | $6.53 Million | $11.09 Million | -18.01pp |
| 2013-12-31 | 76.91% | $12.72 Million | $16.54 Million | -1.47pp |
| 2012-12-31 | 78.38% | $20.83 Million | $26.57 Million | +2.16pp |
| 2011-12-31 | 76.22% | $20.57 Million | $26.98 Million | -8.49pp |
| 2010-12-31 | 84.71% | $38.72 Million | $45.70 Million | -11.14pp |
| 2009-12-31 | 95.85% | $59.48 Million | $62.06 Million | +62.38pp |
| 2008-12-31 | 33.47% | $7.26 Million | $21.68 Million | -33.38pp |
| 2007-12-31 | 66.85% | $18.16 Million | $27.16 Million | -- |
About Omeros Corporation
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinic… Read more